Silence Therapeutics PLC Notice of AGM and Publication of Annual Report (2075E)
May 04 2017 - 6:05AM
UK Regulatory
TIDMSLN
RNS Number : 2075E
Silence Therapeutics PLC
04 May 2017
Notice of AGM and publication of Annual Report
4 May 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that its annual report and financial
statements for the year ended 31 December 2016 ("Annual Report and
Accounts"), including the Notice of Annual General Meeting ("AGM"),
is available for download on the Company's website
www.silence-therapeutics.com. The Annual Report and Accounts will
be posted to shareholders on or before 9 May 2017.
The AGM will be held at 10am on Friday 2 June 2017, at the
offices of Silence Therapeutics Plc, 72 Hammersmith Road, London,
United Kingdom W14 8TH.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Canaccord Genuity Limited (Nominated Tel: +44 (0)20
Adviser and Joint Broker) 7523 8350
Henry Fitzgerald-O'Connor/Emma
Gabriel
Peel Hunt LLP (Joint Broker) Tel: +44 (0)20
James Steel/Oliver Jackson 7418 8900
Media Enquiries: Tel: +44 (0)
FTI Consulting 20 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBGGDUDUGBGRS
(END) Dow Jones Newswires
May 04, 2017 07:05 ET (11:05 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Silence Therapeutics Plc (London Stock Exchange): 0 recent articles
More Silence Ther. News Articles